163 related articles for article (PubMed ID: 29298413)
1. A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model.
Hamilton JR; Vijayakumar G; Palese P
Cell Rep; 2018 Jan; 22(1):1-7. PubMed ID: 29298413
[TBL] [Abstract][Full Text] [Related]
2. A recombinant influenza virus with a CTLA4-specific scFv inhibits tumor growth in a mouse model.
Lei GL; Wang LP; Dong SH; Sun F; Cheng JX; Yang XL; Zhang SG; Wang XL; Wang XX; Yang PH
Cell Biol Int; 2021 Jun; 45(6):1202-1210. PubMed ID: 33501754
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
5. SOCS4 expressed by recombinant HSV protects against cytokine storm in a mouse model.
Ren S; Chen X; Huang R; Zhou GG; Yuan Z
Oncol Rep; 2019 Mar; 41(3):1509-1520. PubMed ID: 30569160
[TBL] [Abstract][Full Text] [Related]
6. H5N1 Influenza A Virus PB1-F2 Relieves HAX-1-Mediated Restriction of Avian Virus Polymerase PA in Human Lung Cells.
Mazel-Sanchez B; Boal-Carvalho I; Silva F; Dijkman R; Schmolke M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563290
[TBL] [Abstract][Full Text] [Related]
7. Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.
Kuryk L; Møller AW; Jaderberg M
J Med Virol; 2019 Sep; 91(9):1702-1706. PubMed ID: 31081549
[TBL] [Abstract][Full Text] [Related]
8. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
9. [Oncolytic potential of recombinant influenza A virus vectors on a model of malignant glioma in vivo].
Shurygina APS; Kartashev AV; Kovanko EG; Kiseleva LN; Pustovalov YI; Slita AK; Zarubaev VV; Belyaevskaya SV; Sirotkin AK; Kiselev OI; Egorov AY
Vopr Onkol; 2016; 62(1):138-45. PubMed ID: 30444592
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Efficacy of an Oncolytic Influenza Virus Carrying an Antibody Against Programmed Cell Death 1 in Hepatocellular Carcinoma.
Lei G; Li B; Yang H; Sun F; Li D; Yan J; Wang Y; Li R; Liu H; Zhang S; Li Y; Yang P
Hum Gene Ther; 2022 Mar; 33(5-6):309-317. PubMed ID: 35018832
[TBL] [Abstract][Full Text] [Related]
11. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic study of intertypic nucleoprotein complex formation and its inhibitory effect toward influenza A virus.
Narkpuk J; Jaru-Ampornpan P; Subali T; Bertulfo FC; Wongthida P; Jongkaewwattana A
Virology; 2015 Nov; 485():104-15. PubMed ID: 26218215
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunoglobulin A specific for influenza A virus hemagglutinin: production, functional analysis, and formation of secretory immunoglobulin A.
Shoji K; Takahashi T; Kurohane K; Iwata K; Matsuoka T; Tsuruta S; Sugino T; Miyake M; Suzuki T; Imai Y
Viral Immunol; 2015 Apr; 28(3):170-8. PubMed ID: 25658886
[TBL] [Abstract][Full Text] [Related]
15. A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.
Wu C; Wu M; Liang M; Xiong S; Dong C
Cell Mol Immunol; 2019 Sep; 16(9):780-782. PubMed ID: 31363172
[No Abstract] [Full Text] [Related]
16. Aurantiamide acetate from baphicacanthus cusia root exhibits anti-inflammatory and anti-viral effects via inhibition of the NF-κB signaling pathway in Influenza A virus-infected cells.
Zhou B; Yang Z; Feng Q; Liang X; Li J; Zanin M; Jiang Z; Zhong N
J Ethnopharmacol; 2017 Mar; 199():60-67. PubMed ID: 28119097
[TBL] [Abstract][Full Text] [Related]
17. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
[TBL] [Abstract][Full Text] [Related]
18. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
Jiang H; Shin DH; Nguyen TT; Fueyo J; Fan X; Henry V; Carrillo CC; Yi Y; Alonso MM; Collier TL; Yuan Y; Lang FF; Gomez-Manzano C
Clin Cancer Res; 2019 Nov; 25(22):6801-6814. PubMed ID: 31455679
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Zamarin D; Holmgaard RB; Ricca J; Plitt T; Palese P; Sharma P; Merghoub T; Wolchok JD; Allison JP
Nat Commun; 2017 Feb; 8():14340. PubMed ID: 28194010
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
